Product
Fasudil
4 clinical trials
5 indications
Indication
Amyotrophic lateral sclerosisIndication
Mild Cognitive ImpairmentIndication
MildIndication
Alzheimer's diseaseIndication
Parkinson's DiseaseClinical trial
A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients With Amyotrophic Lateral Sclerosis (ALS)Status: Active (not recruiting), Estimated PCD: 2023-07-01
Clinical trial
Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALSStatus: Completed, Estimated PCD: 2022-11-30
Clinical trial
A Placebo Controlled Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Early Alzheimer's Disease (FEAD)Status: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease (ROCK-PD)Status: Recruiting, Estimated PCD: 2024-09-30